LataMed AI Corp. (OTC: LMEDD) announced today that its 5-for-1 forward stock split has become effective, marking a significant corporate milestone for the digital health and artificial intelligence company. The split, which was previously disclosed, took effect at the opening of trading following the publication of the corporate action on the FINRA Daily List dated July 14, 2026. As a result, the company's common stock will trade under the temporary symbol LMEDD for approximately 20 business days before reverting to LMED.
The forward stock split is being implemented in conjunction with a mandatory share exchange and a new CUSIP number, 21116R404, while the prior CUSIP, 21116R305, has been suspended. Shareholders holding shares through brokerage accounts or in electronic book-entry form are not required to take any action, as brokerage firms and custodians are expected to process the corporate action automatically. For those holding physical stock certificates, no immediate action is necessary, but when certificates are presented for transfer, sale, or exchange, they will be processed under the new CUSIP.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., emphasized the importance of this step: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms."
The forward stock split is a strategic move to increase the number of shares outstanding, which can enhance liquidity and make the stock more accessible to a broader range of investors. This action often signals management's confidence in the company's future prospects. For LataMed AI, which is still in the development stage, the split aligns with its efforts to build momentum as it targets commercialization of its AI-driven healthcare solutions in emerging markets, particularly Latin America.
The company's focus on telehealth infrastructure, healthcare coordination tools, and AI-enabled platforms positions it to address significant healthcare access challenges in underserved regions. The forward stock split may also facilitate capital-raising activities and attract institutional investors as the company progresses toward revenue generation. Investors are encouraged to review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov for more details on the corporate action and associated risks.
While the forward stock split does not change the company's underlying value, it is a tactical financial maneuver that could support LataMed AI's growth trajectory as it seeks to commercialize its AI platforms. The company's technology, including CardioAI, PulmoAI, and NeuroAI, aims to improve diagnostic capabilities and patient outcomes in regions with limited healthcare resources. As LataMed AI executes its strategy, the forward stock split serves as a reminder of the company's commitment to enhancing shareholder value and advancing its mission to democratize healthcare through artificial intelligence.
